Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Thrombocytopenia occurs when a person's blood has a decreased number of platelets, which are
cells involved in blood clotting. This condition may lead to uncontrolled bleeding and can be
fatal. Thrombocytopenia commonly occurs with hepatitis C virus (HCV) infection or as a result
of standard HCV treatment. Anti-D is an antibody approved by the Food and Drug Administration
(FDA) for the treatment of HIV-related thrombocytopenia. The purpose of this study is to
determine the safety and effectiveness of intravenous anti-D for the treatment of
thrombocytopenia in patients with HCV infection who are starting or already undergoing
treatment with peginterferon alfa-2 and ribavirin. This study will recruit HCV patients both
with and without HIV co-infection.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)